Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitis.
Pediatr Dermatol
; 40(1): 132-134, 2023 Jan.
Article
en En
| MEDLINE
| ID: mdl-36403606
ABSTRACT
In our cohort study, we sought to describe the utilization patterns of systemic immunomodulators in children with atopic dermatitis (AD) and how utilization changed after approval of dupilumab, the first systemic drug approved for the treatment of AD. Using US nationwide claims data, we identified children with AD who initiated a systemic therapy (dupilumab, cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil) from March 2015 to February 2021 and used Sankey plots to describe patterns of starting, switching, and discontinuing these drugs. Dupilumab use among children increased from 19.4% before approval in children to 88.3% after approval in 2019-20. Adherence to dupilumab may suggest better tolerance and improved outcomes in children with AD.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Dermatitis Atópica
Tipo de estudio:
Observational_studies
Límite:
Child
/
Humans
Idioma:
En
Revista:
Pediatr Dermatol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos